Pfizer Continues Positive Data Readouts For JAK Inhibitor Abrocitinib In Eczema

A second Phase III JADE study showed statistically significant skin clearance and reduced pruritus in atopic dermatitis, although safety is harder to evaluate for now. A filing planned for 2020 will include results from a cross-study comparison evaluating abrocitinib versus Dupixent.

woman in a laboratory microscope with microscope slide in hand.toned image.
Pfizer continues to build a case for its JAK1 inhibitor in atopic dermatitis

Both 100mg and 200mg doses of Pfizer Inc.’s selective JAK1 inhibitor abrocitinib demonstrated statistical significance on a pair of skin-clearance measures as well as a secondary endpoint of reducing pruritus in the Phase III JADE MONO-2 study, the company said on 27 September, confirming data for the drug in atopic dermatitis reported in May.

Pfizer’s Michael Corbo, chief development officer for inflammation and immunology, said the company hopes to file abrocitinib for US Food...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Clinical Trials

J&J’s Trispecific Antibody For Myeloma Offers Improved Safety, Potency Over Bispecifics

 

The drugmaker presented data from its Phase I study of JNJ-79635322 at ASCO and EHA showing a 100% response rate in BCMA- and GPRC5D-naïve patients.

ASCO: Pushing The Frontiers Of ADCs

 

Antibody-drug conjugates are a major part of the oncology pipeline, and data presented at the American Society of Clinical Oncology meeting highlight the emergence of new technologies.

Skyhawk Looks To Soar With Huntington’s Hope

 
• By 

Oral RNA splicing modulator has gone into a Phase II/III trial

Scholar Rock Shows Muscle-Building PoC In Obesity

 

The company said it intends to maintain a focus on rare neuromuscular disease with apitegromab but could consider partnering in obesity.

More from R&D